Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Vaginal lactobacillus medicant

A technology of Lactobacillus and medicine, applied in the field of prevention and treatment of vaginal infection, can solve the problems of infection, prevention or treatment of vaginal infection with little effect, lack of ability of microorganisms to combine and settle, etc.

Inactive Publication Date: 2000-07-12
SUZHOU OSEL BIO PHARM
View PDF0 Cites 13 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Because the product may contain inappropriate strains of microorganisms (for example, many contain strains that are difficult to revert to in the vagina), may be infected by other potentially pathogenic microorganisms, have low microbial viability, and / or lack the ability of microorganisms to bind to and colonize the vaginal epithelium, by Therefore, even the use of commercially available Lactobacillus products has little effect on preventing or treating vaginal infections

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Vaginal lactobacillus medicant
  • Vaginal lactobacillus medicant
  • Vaginal lactobacillus medicant

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0114] The following examples demonstrate methods for selecting Lactobacillus strains suitable for use in the present invention.

[0115] Six Lactobacillus strains were isolated from the vagina of six healthy, asexual women, and a series of beneficial properties of these six different Lactobacillus strains were evaluated. The purity of these 6 strains, the ability to adhere to vaginal epithelial cells, the stability of genetic properties, the ability to produce hydrogen peroxide, and the survival stability of long-term storage need to be evaluated. Suitable strains for inclusion should possess: purity (i.e., freedom from contaminating microorganisms), as determined by the ability to maintain substantially pure cultures of the parental strain; a percent vaginal epithelial cell adhesion value of at least approximately 80%; stable genetic performance , by identifying strains in which the genetic properties of the cultured cells are the same as the parental strain, thereby assessi...

Embodiment 2

[0133] The following examples represent the determination of the optimum ratio of cells to preservation matrix that provides high viable numbers of cells of the preserved strain CTV-05.

[0134] plate number

Embodiment 3

[0136] This example describes a specific method for preparing the vaginal medicine of the present invention.

[0137] The composition of the MRS medium used in all experiments was as follows: 10 g hydrazone peptone No. 3 for bacteria, 10 g beef extract for bacteria, 5 g yeast extract for bacteria, 20 g glucose extract for bacteria, 1 g Tween 80, 2 g ammonium citrate , 5g sodium acetate, 0.1g magnesium sulfate, 0.05g manganese sulfate and 2g dipotassium hydrogen phosphate, dilute the above components to 1000ml with reagent grade water. The so-called MRS agar refers to adding 10 g of agar to the above mixture. The medium was adjusted to pH 6.5±0.2 at 25°C.

[0138] Preservation matrices were prepared as follows. 2X gelatin (eg 137.5g / 500ml reagent grade water) and 4X skim milk (eg 15g / 250ml reagent grade water) were autoclaved at about 121°C for about 15 minutes. Mix together 4X xylitol (eg 59g / 250ml reagent grade water) and 4X glucose (eg 25g / 250ml reagent grade water), adju...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Disclosed are novel isolated strains of bacteria of the genus Lactobacillus which are useful in a vaginal medicant. Also disclosed are medicants containing such Lactobacilli, a novel preservation matrix for microorganisms, a method for preserving microbial cells within a medicant, and methods for preventing and treating vaginal and gastrointestinal infections.

Description

[0001] References about government funding [0002] This invention was supported in part by Government AI 31448 and R43 AI 36021-01, both of which were awarded by the National Institutes of Health, and by CDC 200-94-0819, which was awarded by the Centers for Disease Control. The government has certain rights in this invention. field of invention [0003] The present invention relates to bacteria of the genus Lactobacillus having beneficial properties suitable for use in vaginal medicine. The present invention more particularly relates to vaginal medicines having substantially pure cultures of preserved microbial cells, and to preservation matrices, methods of preserving microbial cells within said preservation matrices, and methods for the prevention and treatment of vaginal infections. Background of the invention [0004] Lower genital tract infections, including sexually transmitted diseases (STDs), are some of the most common clinical problems among women of reproductive...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C12N1/20A61K9/00A61K35/74A61K35/747A61K39/00A61K39/02A61K39/09A61K47/10A61K47/26A61K47/42A61P1/00A61P15/00A61P15/02A61P31/00A61P31/04A61P33/00C12R1/225
CPCA61K2039/541A61K35/747C12R1/225C12N11/10A61K39/02A61K39/09A61K2039/52A61P1/00A61P15/00A61P15/02A61P29/00A61P31/00A61P31/04A61P31/18A61P33/00A61P33/02C12R2001/225C12N1/205
Inventor 杰拉尔德·L·克里索普
Owner SUZHOU OSEL BIO PHARM
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com